Compare · HYFT vs NVO
HYFT vs NVO
Side-by-side comparison of MindWalk Holdings Corp. (HYFT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYFT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $208.95B, about 3128.1x HYFT ($66.8M).
- Over the past year, HYFT is down 45.5% and NVO is down 16.4% - NVO leads by 29.1 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 2 for HYFT).
- NVO has more recent analyst coverage (25 ratings vs 0 for HYFT).
- Company
- MindWalk Holdings Corp.
- Novo Nordisk A/S
- Price
- $1.44+2.13%
- $47.19-2.99%
- Market cap
- $66.8M
- $208.95B
- 1M return
- +5.11%
- -7.37%
- 1Y return
- -45.45%
- -16.37%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HYFT
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- AI Found an Influenza Target That Survives Viral Mutation
- SEC Form EFFECT filed by MindWalk Holdings Corp.
- SEC Form 6-K filed by MindWalk Holdings Corp.
- An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
- SEC Form 20-F filed by MindWalk Holdings Corp.
- SEC Form 6-K filed by MindWalk Holdings Corp.
- MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure
- As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
- SEC Form F-3 filed by MindWalk Holdings Corp.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S